The comparative analysis of the pathogenicity of a parental herpes simplex virus type 1 strain and its phosphonoacetic acid (PAA)-resistant and acyclovir (ACV)-resistant mutants showed marked differences among them. After orofacial skin inoculation of hairless mice the parental and PAA-resistant viruses were detected during the first 4 days after infection at high and increasing titers in the trigeminal ganglia; the ACV-resistant mutant was present at low and decreasing titers in the ganglia. Severe and slow-healing skin lesions were produced by the parental and PAA-resistant viruses; mild and rapidly healing lesions were produced by the ACV-resistant mutant. Virus titers in ganglia and the intensity of skin lesions were related to the virus dose used in the primary infection. Latent infections became established in trigeminal ganglia of mice inoculated with 1060 plaque-forming units of the parental or PAA-resistant virus; no latent infections were detected in ganglia of mice inoculated with 107.0 plaque-forming units of the ACV-resistant mutant. Serum antibody titers attained similar values 4 weeks after primary infection with both mutants and the parental virus. Mice infected with the ACV-resistant mutant were reinfected with the parental and PAAresistant viruses; the degree of protection against development of skin lesions, mortality, and latency was related to the dose of ACV-resistant virus used in the primary infection. Mortality was prevented by a dose of 1060 plaque-forming units, skin lesions were prevented by a dose of 1065 plaque-forming units, and latency was prevented by a dose of 107.0 plaque-forming units of the ACV-resistant mutant. Protection against reinfection with the PAA-resistant mutant was achieved with lower doses than protection against the parental virus. Serum antibody titers showed a 4-to 15-fold increase after reinfection. The results suggest that the ACV-resistant, latency-negative mutant has many attributes of a live attenuated herpes simplex virus vaccine.
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With the increase in the use of antiviral compounds active against herpes simplex virus (HSV), the emergence of drug-resistant virus can be expected during the treatment of viral infection. Thus far, however, 5-iodo-2'-deoxyuridine (IUdR)-resistant HSV mutants from treated patients have been isolated infrequently (10, 11, 30) relative ease in vitro by using in the selection procedure a variety of antiviral compounds: IUdR (22) , phosphonoacetic acid (PAA) (15) , arabinosylthymine (Ara-T) (27) , and 9-(2-hydroxyethoxymethyl)guanine (acyclovir; ACV) (5, 6) . Recently, it was reported that arabinosyladenine-resistant mutants were obtained in the presence of high (100-Lg/ml) drug concentrations (28), although earlier attempts to obtain them have failed (13) .
Previous studies have shown that Ara-T-resistant (25, 26) and ACV-resistant mutants (5, 14) have a decreased pathogenicity in experimental animal infections, whereas PAA-resistant mutants (15) have a pathogenicity similar to that of the parental HSV strain. Intermediate degrees of pathogenicity were observed in experimental infections induced by IUdR-resistant mutants (21, 22, 28) . Only Ara-T-and ACV-ity to induce latent infections, whereas PAAand IUdR-resistant mutants were tested only for their potential to induce skin or ocular lesions and a fatal outcome of the infection. The ability of these mutants to invade sensory ganglia during the acute phase of skin infection has not yet been fully investigated.
In this report we present data on the ability of ACV-and PAA-resistant mutants derived from an HSV-1 strain to invade the trigeminal ganglia and to induce skin lesions during the acute phase of orofacial infection of hairless mice. The frequency of latent ganglionic infections in mice surviving the primary infections with drug-resistant and parental viruses was also determined. In addition, mice inoculated with a latency-negative ACV-resistant mutant (11) were reinfected with the PAA-resistant and parental viruses and observed for the development of skin lesions and the establishment of ganglionic latency. We have also determined the level of neutralizing serum antibodies after primary infection and after reinfection of the mice.
MATERLALS AND METHODS
Parental virus and drug-resistant mutants. The parental HSV type 1 (HSV-1) strain S was described in our previous publications (13) (14) (15) . The selection and cloning in microtiter plates of the ACVresistant mutant was described in detail in our recent publication (14) . The mutant stock had a titer of 1068 50% tissue culture infective doses in the absence of ACV and 1065 50% tissue culture infective doses in the presence of ACV (5 ,ug/ml). The PAA-resistant mutant was selected likewise by the passage of the parental strain in the presence of increasing drug concentrations (25, 50 , and 100 ug of PAA per ml), and by cloning in microtiter plates (13 Isolation of latent virus from trigeminal ganglia. Mice were exsanguinated by heart puncture under anesthesia 3 to 4 weeks after the primary infection and at the same interval after reinfection. The trigeminal ganglia were explanted in a 24-well tissue culture plate (Linbro, Camden, Conn.). After the ganglia became attached to the bottom of the well, 2 ml of Eagle minimum essential medium with 2% fetal calf serum (GIBCO Laboratories, Grand Island, N.Y.) was added to each well. After 4 days in culture the ganglia were homogenized by sonication, and after centrifugation the supernatant was tested for the presence of reactivated virus in human foreskin fibroblasts (FS-7 cells). Antiviral compounds. Disodium PAA was obtained from Abbott Laboratories, North Chicago, Ill. The compound was dissolved in phosphate-buffered saline adjusted to pH 7 (ii) ACV-resistant mutant. Similar to the parental virus, the ACV-resistant mutant was detected in trigeminal ganglia by day 2 postinfection (Fig. 2) . However, the titer observed after inoculating 107.0 PFU of the mutant was 10 times lower than that observed after inoculating 1060 PFU of the parental virus. The free virus titers in the ganglia were related to the dose of virus used for inoculation. As opposed to the continuous increase of free virus in trigeminal ganglia of mice inoculated with the parental virus ( Fig.  1) , the titer of free mutant virus showed a continuous decrease over the 4-day observation period ( (Table 1) .
Latent infections were established in almost all mice (92%) inoculated with the parental or PAA-resistant virus with doses of at least 106.0 PFU. Even with a dose of 105-5 PFU, 50% of the mice became latently infected. No latent infection was established in mice inoculated with any dose of the ACV-resistant mutant (Table 1) (Table 3) .
Mice infected with various doses of the ACVresistant mutant had an average neutralizing serum antibody titer of about 2.20 logi0 units (Table 3 ). After reinfection with 106.0 or 107-0 PFU of the parental or PAA-resistant virus the titers increased about 5-to 15-fold (Table 4) . The increase was more pronounced with a challenge dose of 107 PFU than with 106 PFU and stronger with the parental virus than with the PAA-resistant mutant. There was no apparent relation between the extent of the titer increase after reinfection and the dose of the ACV-resistant virus used in the primary inoculation. Reinfection with the parental virus induced on the average a 15-fold (107 PFU) to 4-fold (106 PFU) bDetermined in the single surviving mouse (see Table 1 ). increase, whereas in reinfections with the PAAresistant mutant the increases ranged from more than 6-fold (107 PFU) to almost 4-fold (106 PFU).
DISCUSSION
The comparative analysis of the pathogenicity of the parental HSV-1 strain and its drug-resistant mutants showed marked differences among them. The parental strain was highly pathogenic as indicated by its ability to invade and attain high titers in the trigeminal ganglia during the acute phase of infection, by inducing severe skin lesions, by causing an increased mortality when inoculated at high dose (1070 PFU), and by its ability to induce latent ganglionic infections in all mice, even when inoculated at a relative low dose (1060 PFU). Furthermore, only mice which were inoculated with at least 106.5 PFU of the ACV-resistant mutant showed a satisfactory degree of protection when reinfected with a high dose of the parental strain ( Table 2) .
The PAA-resistant mutant behaved much in the same way as the parental virus. However, the results suggest that this mutant is somewhat less pathogenic: the mortality rate after primary infections was slightly lower, and the invasion of the trigeminal ganglia during the acute phase of the infection proceeded at a slower rate. Mice inoculated with the ACV-resistant mutant showed a better degree of protection against reinfection with the PAA-resistant mutant, and antibody titers elicited after reinfection with a high dose of the mutant (107 0 PFU) were slightly lower than those elicited by the parental strain (Table 4) . None of these criteria was significantly different when examined separately; however, considered together they suggest that the PAA-resistant mutant is less invasive than the parental strain.
Resistance to PAA is caused by a mutation of the deoxyribonucleic acid polymerase gene in the HSV genome, which results in the synthesis of an enzyme insensitive to the inhibitory action of the drug (9) . Whether the observed decreased invasiveness of the PAA-resistant mutant is due solely to the altered polymerase cannot be determined on the basis of the present experiments.
The ACV-resistant mutant proved to be devoid of pathogenicity. The skin lesions were minimal and healed rapidly, and no latent infections were detected in the trigeminal ganglia irrespective of the virus dose employed. Nevertheless, the mutant was able to penetrate in the ganglion, but the titers of free virus during the acute phase of infection were about 100 times lower than those observed with the parental or PAA-resistant virus. Similar results were obtained by Tenser et al. (27) after corneal infection of guinea pigs with an Ara-T-resistant HSV mutant. In addition, free virus in ganglia decreased rapidly, the maximum titer being observed on the first day (day 2 p.i.) when virus became detectable. However, despite this limited presence of the ACV-resistant mutant in the infected mouse, it was sufficient to elicit an immune response adequate to protect mice against reinfection.
ACV acquires antiviral potential through conversion by the HSV-induced thymidine kinase (TK) into its di-and triphosphate (4, 8) . ACVresistant mutants should, therefore, be TK negative. Field and Wildy (7) have shown that HSV TK-negative mutants have a reduced pathogenicity after intracerebral inoculation of mice and a low propensity to induce latent ganglionic infections. Field and Darby (5) confirmed that TK-negative ACV-resistant mutants were attenuated when injected into mice, as indicated by reduced virus replication and inflammatory response of the ears of the animals; in addition, a dose of 1040 PFU did not result in latent infections in cervical ganglia. The latency-negative character of ACV-resistant mutants was confirmed by our previous (14) and present data which show that percutaneous infection with a dose as high as 107.0 PFU does not lead to latent infections in trigeminal ganglia.
Attenuated HSV mutants were isolated also by selection in the presence of Ara-T (27) ; since this drug is likewise phosphorylated into its active form by the viral TK (1), Ara-T-resistant mutants are TK negative. The Ara-T-resistant mutant has a reduced pathogenicity in guinea pigs as reflected by a decreased frequency of latent infections in the trigeminal ganglia after comeal inoculation (27) . It was shown that not all ACV-resistant mutants are TK negative, and that these mutants are not latency negative (5). It appears also that TK-negative and drug-resistant HSV mutants show differences in their ability to induce latent infections; some of the ACV-resistant mutants isolated by Field and Darby (5), as well as the ACV-resistant mutant isolated in our laboratory, are completely latency negative, whereas some TK-negative (7) and Ara-T-resistant (26, 27 ) mutants show only a reduced frequency of latency after primary infections. Since resistance of HSV to ACV results also from a mutation in the deoxyribonucleic acid polymerase locus (3, 24) it is quite possible that ACV-resistant mutants with an increased ability to induce latent infections have a defect in the polymerase instead of the TK locus. Our previous (14) and present data, as well as those obtained in other laboratories (2, 26, 27) , indicate that TK-negative and drug-resistant mutants penetrate the sensory ganglia during the acute phase of infection. Since latency is, however, not established or present only in a small proportion of the infected animals, some possibilities may be considered. (i) The mutants do not establish latent infections, the virus being eliminated by a process of autosterilization. (ii) The mutant becomes established in a defective, non-reactivable form sirnilar to the latent viruses found in human ganglia, which were rescued only upon reinfection with temperature-sensitive mutants (2) . (iii) The mutant may be either totally eliminated or latently established in a defective form, depending on the particular mutants used, the dose of the inoculated virus, the animal species used in the experimental infection, or the route of the primary infection.
The natural outcome of peripheral infection in mice with most wild HSV strains is death from encephalitis (12) . The severity of the infection is controlled by the dose of virus, the route of inoculation, and the strain of mice (20) . We have shown that mice surviving a primary infection with the neurovirulent HSV-1 strain S are resistant to reinfection with a homo-or heterotypic HSV strain. However, this protection against mortality does not prevent the establishment of latency in ganglia not involved during the primary infection (16) . Intraperitoneal inoculation with neurovirulent HSV-1 strains, which does not lead to the establishment of latent infections, produced significant protection against the development of latency after subsequent challenge (23) . Likewise, simultaneous intraperitoneal inoculation with pathogenic and apathogenic HSV-1 strains protects mice against the fatal outcome of infection (25) . Protection against mortality was obtained also by intracerebral inoculation of avirulent HSV strains (18) .
It has been suggested that TK-negative mu- 
